Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy

AIDS

Volumn 15, Issue 12, 2001, Pages 1581-1584

  Walmsley, Sharon L ^a,b   Kelly, Deborah V ^a,e   Tseng, Alice L ^a,b   Humar, Atul ^b   Harrigan, P Richard ^c,d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NONE

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0035902910     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00019     Document Type: Article

References (14)

1. Neverapine: A review of its development, pharmacological profile and potential for clinical use
2. Efavirenz
3. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
4. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
5. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
6. 3: ACTG 208
7. Selection conditions affect the evolution of specific mutations in reverse transcriptase gene associated with resistance to DMP 266
8. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel
9. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
10. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a neverapine plus protease inhibitor-containing regimen
11. Efavirenz and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
12. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine and nevirapine
13. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
14. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database